Other versions:

(Verbatim name)

ID

(Catalog Number)

ORG

DES

Invalid DOI was provided, please try again

XML
PDF
 
 
Twitter
Facebook
Mendeley
Reddit
Notify a colleague
  • ContentsContents
  • Article InfoArticle Info
  • CiteCite
  • MetricsMetrics
  • CommentComment
  • RelatedRelated
  • FigsFigs
  • TabsTabs
  • RefsRefs
  • CitedCited
  • Article title
  • Abstract
  • Keywords
  • 1. Introduction
  • 2. Experimental procedure
    • 2.1. Molecular docking studies
    • 2.2. Chemistry
      • 2.2.1. General methodology for synthesis of 4-ethyl-N-(5-(p-tolyl)-1,3,4-oxadiazol-2-yl) piperazine-1-sulfonamide (8a–8i)
      • 2.2.2. General procedure for synthesis of 1-(pyridin-4-yl)-N-(5-(p-tolyl)-1,3,4-oxadiazol-2-yl) methanimine (22a-22i)
  • 3. In vitro assay for the inhibition of dipeptidyl peptidase-4 (DPP-4)
  • 4. In-vivo anti-diabetic studies
    • 4.1. Acute toxicity study
    • 4.2. An oral glucose tolerance test (OGTT)
    • 4.3. In-vivo study of antihyperglycemic activity in a STZ-induced T2DM model
    • 4.4. Statistical analysis
  • 5. Results and discussion
    • 5.1. Molecular docking
    • 5.2. Chemistry
    • 5.3. In vitro DPP-4 assay and structure-activity relationship studies
    • 5.4. In-vivo study of antihyperglycemic activity in a STZ-induced T2DM model
    • 5.5. Oral glucose tolerance test in rats and the response of test substances on blood sugar levels
  • 6. Conclusion
  • Acknowledgments
  • References
Subscribe to email alerts for current Article's categories
Powered by